Literature DB >> 7493765

T cell receptor usage in autoimmune disease.

C Olive1.   

Abstract

Activated T-cells are believed to play a critical role in the pathogenesis of autoimmune disease. In experimental allergic encephalomyelitis (EAE), an animal model resembling human multiple sclerosis (MS), there is evidence that T cells reactive to myelin basic protein mediate an inflammatory response within the central nervous system leading to demyelination. Furthermore, encephalitogenic T cells express TCR with highly restricted V gene usage and consequently specific forms of immunotherapy directed against V gene products have been successful in preventing and treating EAE. These findings prompted studies into the analysis of TCR repertoire expression in human autoimmune diseases in an attempt to identify the TCR usage of autoreactive and potentially pathogenic T cells. However, this has proved difficult as the autoantigens that drive the T cell response in most human autoimmune disorders are unknown. This review examines the data that have accumulated over the past few years on TCR usage in human autoimmune diseases and is focused largely on rheumatoid arthritis and MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493765     DOI: 10.1038/icb.1995.46

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  2 in total

1.  Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.

Authors:  Burkhard J Manfras; Hans Weidenbach; Karl-Heinz Beckh; Peter Kern; Peter Möller; Guido Adler; Thomas Mertens; Bernhard O Boehm
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 2.  The Emerging Roles of Gamma-Delta T Cells in Tissue Inflammation in Experimental Autoimmune Encephalomyelitis.

Authors:  Sakshi Malik; Muzamil Yaqub Want; Amit Awasthi
Journal:  Front Immunol       Date:  2016-01-29       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.